Circulating markers for prognosis of hepatocellular carcinoma

Bibliography

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44:765-9
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-62
   PubMed Web of Science ®Google Scholar
• Lamb JR, Zhang C, Xie T, et al. Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One 2011;6:e20090
   PubMed Web of Science ®Google Scholar
• Luk JM, Burchard J, Zhang C, et al. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem 2011;286:30706-13
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30
   PubMed Web of Science ®Google Scholar
• Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41
   PubMedGoogle Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
   PubMed Web of Science ®Google Scholar
• Yau T, Pang R, Chan P, Poon RT. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin Pharmacother 2010;11: 2187-98
   PubMed Web of Science ®Google Scholar
• Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943-55
   PubMed Web of Science ®Google Scholar
• Qi J, Wang J, Katayama H, et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013;60:135-42
   PubMed Web of Science ®Google Scholar
• Sakamoto M. Early HCC. diagnosis and molecular markers. J Gastroenterol 2009;44(Suppl 19):108-11
   PubMed Web of Science ®Google Scholar
• Chan KC, Lai PB, Mok TS, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008;54:1528-36
   PubMed Web of Science ®Google Scholar
• Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798-807
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-75
   PubMed Web of Science ®Google Scholar
• Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012;2:e000825
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kosaka N, Tanaka M, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009;14:529-38
   PubMed Web of Science ®Google Scholar
• Li Y, Wu J, Zhang W, et al. Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer 2013;108:99-106
   PubMed Web of Science ®Google Scholar
• Sun S, Poon RT, Lee NP, et al. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 2010;9:1923-30
   PubMed Web of Science ®Google Scholar
• Shao Q, Ren P, Li Y, et al. Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol 2012;41:1061-7
   PubMed Web of Science ®Google Scholar
• Nomura F, Sogawa K, Noda K, et al. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 2012;421:837-43
   PubMed Web of Science ®Google Scholar
• Wong KF, Luk JM. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma. Methods Mol Biol 2012;909:295-310
   PubMedGoogle Scholar
• Brand J, Haslberger T, Zolg W, et al. Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 2006;6:3236-42
   PubMed Web of Science ®Google Scholar
• Baumann S, Ceglarek U, Fiedler GM, et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:973-80
   PubMed Web of Science ®Google Scholar
• Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6
   PubMed Web of Science ®Google Scholar
• Liu T, Qian WJ, Strittmatter EF, et al. High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology. Anal Chem 2004;76:5345-53
   PubMed Web of Science ®Google Scholar
• Shim JH, Han S, Lee YJ, et al. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma. Ann Surg 2013;257(4):708-17
   PubMed Web of Science ®Google Scholar
• Kao WY, Chiou YY, Hung HH, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol 2012;67:429-36
   PubMed Web of Science ®Google Scholar
• Kohles N, Nagel D, Jungst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol 2012;33:33-40
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012;57:101-7
   PubMed Web of Science ®Google Scholar
• Itoh S, Morita K, Ueda S, et al. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol 2009;16:3299-307
   PubMed Web of Science ®Google Scholar
• Lee MH, Kim SU, Kim do Y, et al. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:313-22
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hanbali A, Cotant M, et al. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-906
   PubMed Web of Science ®Google Scholar
• Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005;4:220-6
   PubMedGoogle Scholar
• Zhong C, Wei W, Su XK, et al. Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepatogastroenterology 2012;59:93-7
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Tomoda T, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:1604-11
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9
   PubMed Web of Science ®Google Scholar
• Cao DX, Li ZJ, Jiang XO, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012;18:3923-30
   PubMed Web of Science ®Google Scholar
• Zhang X, You X, Wang Q, et al. Hepatitis B virus X protein drives multiple cross-talk cascade loops involving NF-kappaB, 5-LOX, OPN and Capn4 to promote cell migration. PLoS ONE 2012;7:e31458
   PubMed Web of Science ®Google Scholar
• Dong QZ, Zhang XF, Zhao Y, et al. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology 2013;57(3):1024-34
   PubMed Web of Science ®Google Scholar
• Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:709-17
   PubMed Web of Science ®Google Scholar
• Sun J, Xu HM, Zhou HJ, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1-7
   PubMed Web of Science ®Google Scholar
• Kim SH, Chung YH, Yang SH, et al. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol 2009;15:320-30
   PubMedGoogle Scholar
• Zhou C, Zhou HJ, Zhang XF, et al. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol 2013;20(3):929-37
   PubMed Web of Science ®Google Scholar
• Tamai T, Uto H, Takami Y, et al. Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. World J Gastroenterol 2011;17:4890-8
   PubMed Web of Science ®Google Scholar
• Soroida Y, Ohkawa R, Nakagawa H, et al. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol 2012;57:330-6
   PubMed Web of Science ®Google Scholar
• Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology 2012 [in press]
   PubMedGoogle Scholar
• Kinoshita A, Onoda H, Takano K, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol 2012;29:2800-8
   PubMed Web of Science ®Google Scholar
• Imai N, Kinoshita A, Onoda H, et al. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol 2012 [in press]
   PubMed Web of Science ®Google Scholar
• Chan SL, Mo FK, Wong CS, et al. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012;118:3984-92
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Kubota K, Kita J, et al. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg 2012;203:101-6
   PubMed Web of Science ®Google Scholar
• Morimoto M, Numata K, Moriya S, et al. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res 2012;32:619-23
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726-34
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 2012;57:1013-20
   PubMed Web of Science ®Google Scholar
• Iizuka N, Sakaida I, Moribe T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006;26:4713-19
   PubMed Web of Science ®Google Scholar
• Ren N, Qin LX, Tu H, et al. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:399-407
   PubMed Web of Science ®Google Scholar
• Fu X, Wan S, Hann HW, et al. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer 2012;48:1014-22
   PubMed Web of Science ®Google Scholar
• Xia F, Lai EC, Lau WY, et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012;19:1284-91
   PubMed Web of Science ®Google Scholar
• Tokuhisa Y, Iizuka N, Sakaida I, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403
   PubMed Web of Science ®Google Scholar
• El-Shazly SF, Eid MA, El-Sourogy HA, et al. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma. Int J Biol Markers 2010;25:79-86
   PubMed Web of Science ®Google Scholar
• Wong CM, Wong CC, Lee JM, et al. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012;55:1453-61
   PubMed Web of Science ®Google Scholar
• Boutz DR, Collins PJ, Suresh U, et al. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem 2011;286:18066-78
   Google Scholar
• Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:355-60
   PubMed Web of Science ®Google Scholar
• Qi P, Cheng SQ, Wang H, et al. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011;6:e28486
   PubMed Web of Science ®Google Scholar
• Ding X, Ding J, Ning J, et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep 2012;5:1428-32
   Web of Science ®Google Scholar
• Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010;28:827-38
   PubMed Web of Science ®Google Scholar
• Bustin SA. Why the need for qPCR publication guidelines?--The case for MIQE. Methods 2010;50:217-26
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010;2010:617421
   PubMedGoogle Scholar
• Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26
   PubMed Web of Science ®Google Scholar
• Desitter I, Guerrouahen BS, Benali-Furet N, et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011;31:427-41
   PubMed Web of Science ®Google Scholar
• Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like EpCAM(+) tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013;57(4):1458-68
   PubMed Web of Science ®Google Scholar
• Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol 2012;2012:684802
   PubMedGoogle Scholar
• Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39
   PubMed Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011;6:e24671
   PubMed Web of Science ®Google Scholar
• Wang F, Jing X, Li G, et al. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int 2012;32:644-55
   PubMed Web of Science ®Google Scholar
• Dennis Lo Y, Chiu RW. Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. J Pathol 2011;225:318-23
   PubMed Web of Science ®Google Scholar
• Narayan A, Carriero NJ, Gettinger SN, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012;72:3492-8
   PubMed Web of Science ®Google Scholar
• Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604-10
   PubMed Web of Science ®Google Scholar
• Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011;17:3783-93
   PubMed Web of Science ®Google Scholar
• Fan ZC, Yan J, Liu GD, et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683-91
   PubMed Web of Science ®Google Scholar